Akolat

Roman name

Accolate

Pharmacokinetics

Quickly and completely absorbed from the gastrointestinal (eating reduces the bioavailability of up to 40%). C_max achieved through 3h In the blood of 99% is associated with protein (mainly albuminami). T_1/2 10 h. Metabolised; Presented with the urine (10%) and faeces (89%).

Farmakodinamika

Assists противовоспалительно е Effects. Decreases cellular and necletocny of inflammation, blood pressure, swelling, the influx of Eosinophils to light, products superoksidov alveolarnami macrofagami. Improves the lungs.

Indications

Bronchial asthma (prevention of attacks and supporting basic therapy).

Pregnancy and lactation

Perhaps if the effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity, the children's age to 12 years (security application is not set).

Side-Effects

Headache, a breach of the blood, allergic reactions (urticaria, angioneuroticeski swelling), rash (including vezikuliarnuu), rarely swelling lower limbs, artralgia, mialgia, symptomatic infections, bleeding, bruises education with fractures, agranulozitos to respiratory tract infections in elderly patients, raising whey transaminaz, giperbilirubinemia.

Specific guidance

In deciding whether to demote against Akolata dose corticosteroid had to be careful because in patients with severe bronchial asthma lifting receiving oral corticosteroid rarely cause eozinofilnuyu infiltration (sometimes presented as a syndrome Cerga - Straussa with clinical signs of systemic vasculita).

Patient interaction

Acetylsalicylic acid increases, and erythromycin and theofillin lower level in the plasma. Do effect racumin (lengthens protrombinovoe time).

Precautions

There are encouraged to nominate the human liver. Avoid sudden transition from treatment korticosteroidami (inhalants or oral) to Akolatu.

Dosing and Administration

Inside (not to be taken in conjunction with the food), adults and children over 12 years of age, primary and supporting dose : 20 mg twice a day, for children from 7 to 11 years (inclusive), the Infant and supporting dose : 10 mg twice a day, in patients with impaired renal dose adjustment is not required. The course of treatment time.

Storage conditions

List B. The temperature is not above 30 ° C

Shelf life

3 years

The registration

013547/01-2001

Directory → Intermedianta → Prostaglandins, tromboksana, lakotriena and their antagonists → Akolat